This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Classification and special reduction | ICD-10: I33 (acute and subacute endocarditis) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
|---|---|
| Synonyms | Infective endocarditis, bacterial endocarditis, vegetative endocarditis, infective endocarditis (IE), bacterial endocarditis, subacute bacterial endocarditis (SBE) |
| Age of onset | Can occur at any age; most common in people in their 50s–70s due to population aging and more procedures; in their 20s–40s among people who inject drugs |
| 1. History | Go to section |
| 2. Causes | Go to section |
| 3. Genetics | Go to section |
| 4. General epidemiology | Go to section |
| 5. Pathophysiology | Go to section |
| 6. Symptoms | Go to section |
| 7. Signs | Go to section |
| 8. Screening | Go to section |
| 9. Diagnosis | Go to section |
| 10. Treatment | Go to section |
| 11. Prognosis | Go to section |
| 12. Prevention | Go to section |
| 13. References | Go to section |
Historical descriptions of infective endocarditis (IE) date back to the 17th century. In 1646 Lazare Rivière first described endocardial lesions, and in 1809 Jean-Nicolas Corvisart systematically analyzed the association between heart valve damage and systemic symptoms. However, the foundation of today's clinical understanding was laid in William Osler's Gulstonian Lectures of 1885. Osler named IE "ulcerative endocarditis" and systematized its diverse systemic signs, including cerebral embolism, splenomegaly and nodular lesions of the fingertips (Osler nodes). His disease classification was used in clinical practice for more than 100 years.
Before the antibiotic era, the mortality of IE approached 100%. The introduction of penicillin in the 1940s revolutionized the prognosis of the disease, making survival possible in some patients. In 1944 Loewe et al. first reported successful treatment with penicillin, and combination antibiotic therapy subsequently became the standard of care.
The history of the diagnostic criteria is also important. In 1981 von Reyn et al. proposed the Beth Israel criteria, which integrated clinical, microbiological and pathological criteria, and in 1994 Durack and Lukes published the Duke criteria, which included echocardiographic findings. The Duke criteria were later modified by Li et al. in 2000 (Modified Duke criteria), adding Staphylococcus aureus bacteremia, Q fever serology and others to the major criteria, and they remain the standard diagnostic criteria today. The 2023 ESC guidelines further improved diagnostic sensitivity by including nuclear imaging such as 18F-FDG PET/CT and radiolabeled leukocyte SPECT/CT among the major diagnostic criteria.
On the treatment side, advances in prosthetic valve surgical techniques in the 1960s–1970s greatly changed IE management. The endocarditis team concept emerged in the 2010s, and a multidisciplinary approach involving cardiology, infectious diseases, cardiac surgery, neurology and radiology has been shown to contribute to reduced mortality.
Infective endocarditis is caused by a variety of microorganisms, including bacteria, fungi and, rarely, rickettsiae and chlamydiae. The distribution of causative organisms differs by geographic location, route of infection, valve type (native or prosthetic) and patient characteristics.
Gram-positive cocci account for about 80% of all cases. Staphylococcus aureus is currently the most common causative organism in developed countries; it follows an acute course, with rapid progression of valve destruction and systemic embolism. Its proportion is especially high in healthcare-associated IE, prosthetic valve IE, IE in hemodialysis patients and IE in people who inject drugs. Coagulase-negative staphylococci (CoNS) such as Staphylococcus epidermidis are the main cause of early prosthetic valve IE (within 1 year of implantation).
The Streptococcus viridans group (especially S. sanguinis, S. mitis, S. mutans) are commensal oral bacteria and the classic cause of native valve endocarditis through bacteremia after dental procedures. They follow a subacute course and mainly involve left-sided valves. Streptococcus bovis (now S. gallolyticus) is strongly associated with colorectal neoplasms, so colonoscopy must be performed whenever this organism is detected.
Enterococcus faecalis is a major cause of IE after urologic and gastrointestinal procedures, and antibiotic resistance (especially high-level aminoglycoside resistance and vancomycin-resistant enterococci, VRE) makes treatment difficult. The HACEK group (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) are commensal oral bacteria that cause subacute IE, and detection may be delayed because cultures are negative.
Fungal endocarditis is rare, at 2–4% of all cases, but its mortality reaches 50–70%. Candida and Aspergillus account for most cases, and it occurs mainly in patients with long-term central venous catheters, those on immunosuppressants, and solid organ or hematopoietic stem cell transplant recipients. Cultures are often negative, so diagnosis tends to be delayed.
Culture-negative IE (CNIE) accounts for about 5–31% of all IE (varying by region), and prior antibiotic administration is the most common cause. Special pathogens such as Coxiella burnetii (Q fever), Bartonella species, Brucella and Tropheryma whipplei should also be considered, and serology, PCR and metagenomic sequencing (mNGS) are useful for diagnosis.
Infective endocarditis itself is not a genetic disease, but many of the structural heart diseases that raise its risk have a genetic predisposition. Bicuspid aortic valve (BAV), which occurs in about 1–2% of the population, is the most common congenital heart malformation and is associated with variants in genes such as NOTCH1, GATA5 and ROBO4. Patients with BAV have about 2–3 times the risk of native valve IE compared with the general population, and about 15% of all IE patients have BAV as the underlying condition.
Congenital heart malformations (ventricular septal defect, tetralogy of Fallot, transposition of the great arteries, etc.) are important risk factors for IE. Among them, 22q11.2 deletion syndrome (DiGeorge syndrome) is well known as a genetic cause of congenital heart malformations with conotruncal defects. Marfan syndrome (FBN1 variants) and Ehlers-Danlos syndrome cause mitral valve prolapse (MVP), raising the risk of IE.
Host immunogenetics also influences susceptibility to IE. FcγRIIa (CD32) polymorphisms are related to the efficiency of the immune response to staphylococcal infection, and studies have linked certain haplotypes to the risk of developing IE. Loss-of-function variants in Toll-like receptor (TLR) genes, particularly TLR2 and TLR4, can weaken the immune response to bacterial cell wall components and raise the risk of IE.
Pharmacogenetics also affects treatment. Variants such as the SLC22A2 gene variant associated with vancomycin nephrotoxicity and the mitochondrial 12S rRNA (mt-rRNA) MT-RNR1 1555A>G variant associated with aminoglycoside ototoxicity can be considered in antibiotic selection and dose adjustment. Pharmacogenomic testing is clinically meaningful especially in patients at high risk of aminoglycoside-related hearing loss.
Genetic studies of IE in East Asian populations, including Koreans, are still limited. However, some HLA-DR alleles known as a genetic predisposition to rheumatic heart disease (RHD) have been reported in Koreans, and RHD-associated IE remains an important problem in developing countries.
The annual incidence of infective endocarditis is reported as 3–10 per 100,000 population, varying widely by region, age and underlying disease. In developed countries, about 30,000–40,000 cases of IE are estimated to occur annually. The sex distribution shows male predominance (male:female ≈ 2:1), and incidence has been rising over recent decades due to population aging, more healthcare-related procedures and a growing number of hemodialysis patients.
The age distribution shows a bipolar pattern. In developed countries it occurs most often in people in their 50s–70s, and the median age is gradually rising from 50–60 years to 60–70 years. In developing countries, by contrast, IE in young patients with underlying rheumatic heart disease is still common. In people who inject drugs (PWID), right-sided IE in their 20s–40s is characteristic.
By underlying heart disease, people with prosthetic valves have the highest risk of IE (0.3–1.2% per year), and congenital heart malformations, prior IE, hemodialysis, organ transplantation and immunosuppressive therapy are major risk factors. In developed countries today, IE with underlying degenerative valve disease (aortic valve calcification, MVP) is far more common than IE associated with rheumatic heart disease. In addition, IE related to cardiac implantable electronic devices (CIED: pacemakers, defibrillators, resynchronization therapy devices) is increasing rapidly along with device implantation.
In-hospital mortality remains high at about 15–25%, and overall 1-year mortality reaches about 25–40%. The main causes of death are, in order, heart failure (60%), stroke (25%) and sepsis (15%). Operative mortality in patients with severe IE requiring surgical treatment is 10–15%.
Domestic studies report an IE incidence in Korea of about 1.5–3 per 100,000 population, but this may be an underestimate due to limitations of diagnostic criteria and insurance claims data. In Korea, too, Staphylococcus aureus and viridans streptococci are the main causative organisms, followed by Streptococcus bovis, enterococcus and others.
The development of infective endocarditis consists of three broad stages: endothelial injury, bacteremia and vegetation formation.
Stage 1: endothelial injury and sterile thrombus formation. The normal endocardium resists bacterial adhesion, but when the endothelium is damaged by high-velocity or turbulent flow, foreign material (prosthetic valves, catheters) or valve abnormalities (regurgitation, stenosis), the subendothelial extracellular matrix (fibronectin, collagen, laminin) is exposed. Platelets and fibrin deposit at the site to form nonbacterial thrombotic endocarditis (NBTE), which provides a substrate to which bacteria can adhere. Systemic inflammatory states, antiphospholipid antibody syndrome and malignancy (marantic endocarditis) also promote NBTE.
Stage 2: bacteremia. Bacteria enter the bloodstream through dental, gastrointestinal, urologic or skin procedures, intravenous catheter manipulation, or poor oral hygiene (bacterial entry during toothbrushing). Most transient bacteremia is rapidly cleared by normal immunity, but when NBTE is present and bacteria adhere to this substrate, clearance becomes difficult.
Stage 3: vegetation formation and growth. Once bacteria bind to the platelet-fibrin matrix through surface proteins such as fibronectin-binding protein (FnBP) and clumping factors (ClfA, ClfB), additional platelets, fibrin, inflammatory cells and bacteria build up in layers around them and the vegetation grows. The interior of the vegetation is largely avascular, limiting access of antibiotics and immune cells, so a high bacterial density (10⁹–10¹¹ CFU/g) is maintained; this underlies antibiotic resistance and relapse.
When a vegetation grows beyond a certain size, it leads to valve destruction (perforation, rupture, chordal rupture), invasion of surrounding structures (perivalvular abscess, fistula) and hemodynamic failure. When vegetation fragments break off, systemic embolism occurs: in left-sided IE the brain (stroke, silent cerebral infarction), spleen, kidneys and peripheral vessels are targeted, while in right-sided IE pulmonary embolism is the main complication.
Immune activation is also an important part of the pathophysiology. Chronic bacteremia produces circulating immune complexes (CIC), which deposit in the renal glomeruli (glomerulonephritis), joints (arthritis), skin (Janeway lesions, Osler nodes) and retina (Roth spots), causing vasculitis and immune complex–mediated tissue injury.
The symptoms of infective endocarditis vary greatly depending on the virulence of the causative organism, the valves and cardiac structures involved, and the presence of systemic embolism. Acute IE caused by Staphylococcus aureus progresses rapidly within days with high fever, chills and sepsis syndrome, whereas subacute IE caused by viridans streptococci progresses slowly over weeks to months.
Systemic symptoms are the most common. Fever occurs in 80–90% and is often accompanied by night sweats and chills. Nonspecific symptoms such as malaise, fatigue, anorexia and weight loss are also common, so it is easily mistaken early on for a cold or tuberculosis. In elderly, immunosuppressed and chronic kidney failure patients, fever may be absent or only low-grade, delaying diagnosis.
Characteristic cardiac symptoms are a new heart murmur or a change in an existing murmur. Rapid worsening of valvular regurgitation causes heart failure symptoms (exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, leg edema), which are signs of severe IE. Chest pain can occur with myocardial invasion from a perivalvular abscess or with left coronary artery embolism.
Neurological symptoms occur in 20–40% of all IE patients and strongly affect prognosis. Ischemic stroke (cerebral embolism) is the most common (15–20%), and symptomatic intracerebral hemorrhage (rupture of an infectious aneurysm), brain abscess and meningitis can also occur. Headache, hemiplegia, aphasia and altered consciousness may appear, and asymptomatic cerebral infarcts are detected on MRI in up to 80%.
Urologic and musculoskeletal symptoms also occur. Renal emboli cause flank pain, and splenic emboli cause left upper abdominal pain. Arthralgia and myalgia can progress to septic arthritis, either immune complex–mediated or from direct hematogenous seeding. Vertebral osteomyelitis (vertebral IE) presents with low back pain and arises from hematogenous spread.
Various characteristic signs may be seen on physical examination, but these signs are less common in modern IE than in the past.
Cardiac auscultation findings: A new or changed heart murmur is the most important clinical sign. A high-pitched diastolic regurgitant murmur is characteristic of aortic valve IE, and a systolic regurgitant murmur of mitral valve IE. In acute severe valvular regurgitation the murmur may not be loud; instead, an abrupt drop in blood pressure and rise in heart rate are indicators of severity.
Peripheral signs: Osler nodes—tender, reddish-purple nodules on the pulp of the fingertips and toes—result from immune complex vasculitis and are more common in subacute IE (incidence 10–25%). Janeway lesions—painless hemorrhagic macules on the palms and soles—appear mainly in acute S. aureus IE and result from septic emboli. Splinter hemorrhages—linear hemorrhages in the nail beds—are nonspecific, but multiple ones suggest IE.
Ophthalmic signs: Roth spots—retinal hemorrhagic lesions with a pale center—result from immune complex retinal vasculitis and are identified on funduscopic examination. Subconjunctival hemorrhages (petechial hemorrhage) may also appear.
Abdominal signs: Splenomegaly appears in about 30–50% of chronic and subacute IE and suggests splenic infarction or splenic abscess formation. Costovertebral angle tenderness from renal emboli and signs of peritoneal irritation may also be observed.
Neurological signs: Focal neurological deficits (hemiplegia, facial palsy, aphasia, etc.) suggest cerebral embolism. Signs of raised intracranial pressure (headache, nausea, neck stiffness) indicate meningitis or increased intracranial pressure. A decreased level of consciousness is a poor prognostic factor suggesting septic encephalopathy or an intracerebral lesion.
Other: Digital clubbing may appear in chronic IE lasting months or longer. Flushing, sweating and tachycardia due to high fever are also commonly observed. In prosthetic valve IE there is often no new murmur on auscultation, so IE must always be excluded in prosthetic valve patients with fever of unknown origin.
There is no defined mass screening program, but the key is to suspect IE early in high-risk groups and proceed rapidly with the diagnostic workup.
Blood cultures are the most important initial test. Before antibiotics are given, 3 sets (6 blood culture bottles: 3 aerobic and 3 anaerobic) are drawn from different venipuncture sites, ideally 30–60 minutes apart. Both the US IDSA and the ESC 2023 guidelines recommend 3 sets of blood cultures before antibiotic administration. The blood culture positivity rate is about 85–90%. Adequate culture volume (adults: 8–10 mL per bottle) and a total of 3 sets maximize sensitivity.
Echocardiography should be performed immediately when IE is suspected. Transthoracic echocardiography (TTE) is the first-line test, and transesophageal echocardiography (TEE) is performed if TTE image quality is poor or the suspicion of IE is high. TEE is significantly more sensitive than TTE for vegetations, abscesses, fistulas and prosthetic valve IE (sensitivity TTE 70% vs. TEE 96%).
Blood tests: Inflammatory markers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cells (neutrophil predominance) and procalcitonin are elevated but nonspecific. A positive rheumatoid factor (RF) and low serum complement (C3, C4) suggest an immune complex–mediated process. Microscopic hematuria and proteinuria on urinalysis suggest accompanying glomerulonephritis.
In high-risk groups (patients with prosthetic valves, CIEDs, congenital heart malformations or prior IE), diagnostic testing for IE should begin immediately when unexplained fever persists for 2–3 days or more, or in every case of confirmed S. aureus bacteremia. IE is diagnosed in about 15–25% of patients with S. aureus bacteremia.
The Modified Duke criteria (2000, Li et al.) are still used as the standard diagnostic criteria for IE, and the 2023 ESC guidelines added nuclear imaging criteria, improving diagnostic sensitivity.
Major criteria: ① Microbiological criterion—typical IE microorganisms (viridans streptococci, S. bovis, HACEK, S. aureus, enterococcus) positive in 2 or more separate blood cultures, or persistent bacteremia (positive blood cultures ≥12 hours apart, or all of 3 or more blood cultures positive), or Coxiella burnetii IgG antibody ≥1:800. ② Imaging criterion—on echocardiography, vegetation, abscess/pseudoaneurysm/fistula, valve perforation/aneurysm, or new partial dehiscence of a prosthetic valve; or abnormal tracer uptake around a prosthetic valve on 18F-FDG PET/CT (3 months or more after implantation); or abnormal uptake around a prosthetic valve on radiolabeled leukocyte SPECT/CT.
Minor criteria: ① Predisposition (structural heart disease, injection drug use), ② fever (≥38°C), ③ vascular phenomena (emboli, mycotic aneurysm, intracranial hemorrhage, conjunctival petechiae, Janeway lesions), ④ immunologic phenomena (glomerulonephritis, Osler nodes, Roth spots, positive RF), ⑤ microbiological evidence not meeting a major criterion.
Diagnostic classification: 2 major criteria, 1 major + 3 minor, or 5 minor—definite. 1 major + 1–2 minor, or 3 minor—possible. Not meeting any category, resolution of symptoms within 48 hours of antibiotic treatment, or no IE findings at surgery or autopsy—rejected.
Additional imaging: Non-contrast and contrast CT are useful for evaluating perivalvular structures (abscess, pseudoaneurysm, fistula) and embolic complications (brain, spleen, kidneys, mesentery). Brain MRI is superior to CT for detecting silent cerebral infarction, hemorrhage and brain abscess and is recommended before surgery in all patients with left-sided IE. FDG PET/CT is useful especially in diagnosing prosthetic valve IE and CIED-associated IE when echocardiography alone is insufficient. Dental panoramic X-ray or oral CT is used to look for an odontogenic source (dental infection focus).
The core of IE treatment is prolonged intravenous bactericidal antibiotics and, when needed, surgical intervention. An approach in which a multidisciplinary endocarditis team (IE team)—cardiology, infectious diseases, cardiac surgery, neurology, radiology and microbiology—works together is recommended as Class I, Level B in the ESC 2023 guidelines.
Antimicrobial therapy: Standard treatment durations by causative organism are as follows. ① Penicillin-susceptible viridans streptococci/S. bovis native valve IE: penicillin G or ceftriaxone for 4 weeks (or a 2-week short-course regimen with gentamicin). ② S. aureus native valve IE: if methicillin-susceptible (MSSA), nafcillin/oxacillin or cefazolin for 4–6 weeks; if MRSA, vancomycin for 6 weeks. ③ S. aureus prosthetic valve IE: for MRSA, vancomycin 6 weeks + rifampin 6 weeks + gentamicin 2 weeks. ④ Enterococcal IE: ampicillin+ceftriaxone for 6 weeks (high-level aminoglycoside resistance, HLAR) or ampicillin+gentamicin for 4–6 weeks. ⑤ HACEK group: ceftriaxone for 4 weeks. In culture-negative IE, empiric broad-spectrum therapy (ceftriaxone ± gentamicin ± doxycycline) is given while testing for special pathogens in parallel.
Therapeutic drug monitoring (TDM) of vancomycin based on AUC/MIC and monitoring of renal function are essential. The 2020 joint ASHP/IDSA/SIDP guideline recommends Bayesian TDM targeting an AUC₂₄/MIC of 400–600.
Indications for surgery (ESC 2023, Class I): ① heart failure that cannot be controlled with medical therapy (acute severe aortic or mitral regurgitation, cardiopulmonary bypass obstruction), ② locally uncontrolled infection (abscess, pseudoaneurysm, fistula, enlarging vegetation, or fever persisting 7 days or more despite antibiotic treatment), ③ prevention of embolism (left-sided IE with vegetation length >10 mm and 1 or more prior embolic events, or a vegetation >15 mm). Timing of surgery is classified as emergent (within 24 hours), urgent (within a few days) and elective (after completion of antibiotic treatment). Timing of surgery after stroke requires an individualized approach; waiting at least 72 hours after most ischemic strokes and at least 4 weeks after hemorrhagic stroke is recommended.
In CIED-associated IE, complete device removal (including leads) is the rule, by percutaneous lead extraction or surgical removal. The duration of antibiotic treatment is at least 2 weeks after device removal, but 4–6 weeks if valve IE is also present.
Infective endocarditis remains a serious infectious disease with high mortality even in modern medicine. In-hospital mortality is about 15–25%, and 1-year mortality reaches about 25–40%. Factors affecting prognosis are divided into patient factors, causative organisms, and valve and complication factors.
Poor prognostic factors: patient characteristics—older age, prosthetic valve IE, diabetes, immunosuppression, chronic kidney failure; microbiology—S. aureus (MRSA > MSSA), non-S. aureus gram-negative bacteria, fungi; complications—heart failure (the strongest prognostic factor), stroke, kidney failure, septic shock and perivalvular abscess suggest a poor prognosis.
Stroke increases overall mortality in IE patients 2–3-fold, and hemorrhagic stroke in particular carries a very poor prognosis. Progression to multiorgan failure requires intensive care unit (ICU) management, and mortality can exceed 50%.
Operative mortality in patients undergoing surgery is 10–15% for surgery during active IE. However, the benefit of surgery should be considered, given that mortality is higher when surgery is not performed in patients with indications for it (severe heart failure, abscess, etc.). The 5-year survival rate after surgery is about 60–70%.
The recurrence rate is about 2–6% in native valve IE and 6–8% in prosthetic valve IE; causes of recurrence include inadequate antibiotic treatment, failure to remove the source focus, resistant organisms and immunosuppression. Recurrent IE has higher mortality than the first episode.
In the long term, IE survivors may have a markedly reduced quality of life due to complications such as prosthetic valve implantation, heart failure, kidney failure and neurological sequelae (hemiplegia, cognitive impairment). After IE, follow-up care such as oral hygiene, intravenous catheter care and reassessment of the need for antibiotic prophylaxis is also important.
IE prevention consists of oral hygiene, antibiotic prophylaxis before high-risk procedures and early treatment of infection foci. However, the indications for prophylactic antibiotics are narrower than in the past.
Indications for antibiotic prophylaxis: According to the ESC 2023 and revised AHA 2021 guidelines, prophylactic antibiotics are recommended only for the highest-risk groups undergoing dental procedures (manipulation of gingival or periapical tissue, or perforation of the oral mucosa). The high-risk groups are ① people with prosthetic valves (bioprosthetic or mechanical), ② those with prior IE, ③ those with certain congenital heart malformations with residual defects after surgery (cyanotic, within 6 months after implantation of prosthetic material, or permanent residual leak), and ④ heart transplant recipients who develop valve disease. Simple acquired valve disease (aortic stenosis, MVP) and moderate congenital malformations were excluded from prophylaxis.
Standard prophylactic antibiotic regimen: amoxicillin 2 g orally (or amoxicillin/ampicillin 2 g intravenously), a single dose 30–60 minutes before the procedure. With penicillin allergy, clindamycin 600 mg orally or azithromycin/clarithromycin 500 mg orally. For non-dental procedures (gastrointestinal, urologic, respiratory) the evidence for prophylaxis is insufficient, and it is no longer generally recommended.
Non-pharmacologic prevention: Oral hygiene through daily toothbrushing and flossing is more important than antibiotic prophylaxis in preventing most IE (caused by everyday bacteremia unrelated to dental procedures). In people who inject drugs, addiction treatment programs and needle exchange programs reduce the risk of IE. To prevent healthcare-associated IE, aseptic technique during central venous catheter insertion, early removal of unnecessary catheters, glycemic control (in diabetic patients) and care of hemodialysis access are important. People with a history of IE should keep up dental checkups at least twice a year and be educated to visit a medical facility immediately if they develop fever.
Research is under way on vaccines targeting S. aureus to prevent IE, but no vaccine is clinically available to date.